PLX R&D Expenses
Protalix Biotherapeutics Inc · R&D Expenses
PLX R&D Expenses
Latest reported$4.35Mperiod ending
PLX Quarterly R&D Expenses ($0.00 → $4.35M)
Quarterly R&D Expenses
High-resolution chart · PNG
PLX r&d expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 4,351,000 | |
| 5,426,000 | |
| 5,635,000 | |
| 4,467,000 | |
| 5,992,000 | |
| 3,475,000 | |
| 4,123,999 | |
| 2,998,000 | |
| 2,961,000 | |
| 2,887,000 | |
| 3,102,000 | |
| 3,669,000 | |
| 4,475,000 | |
| 5,847,000 | |
| 5,617,000 | |
| 7,386,000 | |
| 7,579,000 | |
| 8,767,000 | |
| 7,641,000 | |
| 7,282,000 | |
| 7,689,000 | |
| 7,122,000 | |
| 10,953,000 | |
| 7,688,000 | |
| 9,186,000 | |
| 10,340,000 | |
| 9,595,000 | |
| 10,000,000 | |
| 13,323,000 | |
| 11,698,000 | |
| 9,969,000 | |
| 10,071,000 | |
| 7,241,000 | |
| 6,443,000 | |
| 8,990,000 | |
| 6,389,000 | |
| 8,826,000 | |
| 4,629,000 | |
| 5,708,000 | |
| 5,056,000 | |
| 7,819,000 | |
| 6,025,000 | |
| 7,698,000 | |
| 5,260,000 | |
| 6,471,000 | |
| 6,762,000 | |
| 4,516,000 | |
| 6,105,000 | |
| 4,962,000 | |
| 6,067,000 | |
| 7,398,000 | |
| 5,637,000 | |
| 6,458,000 | |
| 5,323,000 | |
| 7,889,000 | |
| 6,363,000 | |
| 8,855,000 | |
| 6,844,000 | |
| 7,535,000 | |
| 7,918,000 | |
| 7,319,000 | |
| 8,271,000 | |
| 9,559,000 | |
| 3,546,000 | |
| 10,026,000 | |
| 7,348,000 | |
| 8,531,000 | |
| 4,611,000 | |
| 4,702,000 | |
| 3,794,000 | |
| 4,828,000 | |
| 5,404,000 | |
| 2,882,000 | |
| 4,287,000 | |
| 4,790,000 | |
| 3,445,000 | |
| 2,832,000 | |
| 1,794,000 | |
| 3,773,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |